Cargando…

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis

SIMPLE SUMMARY: In this study, we investigated the impact of immune-related adverse events (irAEs) on the survival of advanced melanoma patients treated with immune-checkpoint inhibitors, as well as the effect of corticosteroids and other immune-modulators on clinical outcome. We summarized the kine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dimitriou, Florentia, Staeger, Ramon, Ak, Melike, Maissen, Matias, Kudura, Ken, Barysch, Marjam J., Levesque, Mitchell P., Cheng, Phil F., Dummer, Reinhard, Mangana, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8230729/ https://www.ncbi.nlm.nih.gov/pubmed/34208218 http://dx.doi.org/10.3390/cancers13122931

Ejemplares similares

A new B-Raf inhibitor combo for advanced melanoma
por: Barysch, Marjam-Jeanette, et al.
Publicado: (2018)

Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Correction: Kudura et al. Prediction of Early Response to Immune Checkpoint Inhibition Using FDG-PET/CT in Melanoma Patients. Cancers 2021, 13, 3830
por: Kudura, Ken, et al.
Publicado: (2022)

Sarcoid-like reactions in patients receiving modern melanoma treatment
por: Dimitriou, Florentia, et al.
Publicado: (2018)

How I treat metastatic melanoma
por: Dummer, Reinhard, et al.
Publicado: (2019)

Hair Depigmentation and Hair Loss in Advanced Melanoma Treated with Combined Immunotherapy and Targeted Therapy
por: DIMITRIOU, Florentia, et al.
Publicado: (2020)

Triple Combination of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in BRAFV600 Melanoma: Current Status and Future Perspectives
por: Welti, Michèle, et al.
Publicado: (2022)

Melanoma patients with additional primary cancers: a single-center retrospective analysis
por: Dimitriou, Florentia, et al.
Publicado: (2019)

Malignancy Rate of Indeterminate Findings on FDG-PET/CT in Cutaneous Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2021)

Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2022)

Addendum: Impact of Covid-19 on the management of patients with metastatic melanoma
por: Welti, Michèle, et al.
Publicado: (2023)

Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor‐related myocarditis and myositis: rechallenge?
por: Rossi, Valentina A., et al.
Publicado: (2023)

A Longitudinal Analysis of IDO and PDL1 Expression during Immune- or Targeted Therapy in Advanced Melanoma()
por: Krähenbühl, Lukas, et al.
Publicado: (2018)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

Coexpression of SOX10/CD271 (p75(NTR)) and β-Galactosidase in Large to Giant Congenital Melanocytic Nevi of Pediatric Patients
por: Barysch, Marjam J., et al.
Publicado: (2014)

Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome
por: Simic, Dario, et al.
Publicado: (2021)

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland
por: Mangana, Joanna, et al.
Publicado: (2017)

Sex-Related Differences in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibition
por: Kudura, Ken, et al.
Publicado: (2022)

Toxicity of combined targeted therapy and concurrent radiotherapy in metastatic melanoma patients: a single-center retrospective analysis
por: Ziegler, Johanna S., et al.
Publicado: (2020)

Long-term pegylated interferon-α and its potential in the treatment of melanoma
por: Dummer, Reinhard, et al.
Publicado: (2009)

Inflammatory Blood Parameters as Biomarkers for Response to Immune Checkpoint Inhibition in Metastatic Melanoma Patients
por: Kudura, Ken, et al.
Publicado: (2022)

The role of cyclin D1 and Ki‐67 in the development and prognostication of thin melanoma
por: Kaufmann, Corina, et al.
Publicado: (2020)

Diffuse Cutaneous Melanosis Associated with Malignant Melanoma
por: Mangana, Joanna, et al.
Publicado: (2015)

Clock-like Mutation Signature May Be Prognostic for Worse Survival Than Signatures of UV Damage in Cutaneous Melanoma
por: Fröhlich, Fabienne, et al.
Publicado: (2023)

Recurrent squamous cell carcinoma of the perianal skin: a case report
por: Staeger, Ramon, et al.
Publicado: (2020)

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Health‐related quality of life in survivors of advanced melanoma treated with anti‐PD1‐based immune checkpoint inhibitors
por: Looman, E. L., et al.
Publicado: (2023)

Correction: Establishing standardized immune phenotyping of metastatic melanoma by digital pathology
por: Sobottka, Bettina, et al.
Publicado: (2021)

Loss of YY1, a Regulator of Metabolism in Melanoma, Drives Melanoma Cell Invasiveness and Metastasis Formation
por: Guendisch, Ulf, et al.
Publicado: (2022)

Cutaneous Adverse Events of Systemic Melanoma Treatments: A Retrospective Single-Center Analysis
por: Kraehenbuehl, Lukas, et al.
Publicado: (2023)

Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients
por: Fässler, Mirjam, et al.
Publicado: (2019)

Improved Survival Prediction by Combining Radiological Imaging and S-100B Levels Into a Multivariate Model in Metastatic Melanoma Patients Treated With Immune Checkpoint Inhibition
por: Burgermeister, Simon, et al.
Publicado: (2022)

The Prognostic Value of a Single, Randomly Timed Circulating Tumor DNA Measurement in Patients with Metastatic Melanoma
por: Boerlin, Aurelio, et al.
Publicado: (2022)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Keratinocytic Malfunction as a Trigger for the Development of Solar Lentigines
por: Barysch, Marjam Jeanette, et al.
Publicado: (2019)

Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect
por: Boegeholz, J., et al.
Publicado: (2020)

Clinicopathological and Genomic Profiles of Atypical Fibroxanthoma and Pleomorphic Dermal Sarcoma Identify Overlapping Signatures with a High Mutational Burden
por: Ak, Melike, et al.
Publicado: (2021)

Improved detection of in-transit metastases of malignant melanoma with BSREM reconstruction in digital [(18)F]FDG PET/CT
por: Liberini, Virginia, et al.
Publicado: (2021)

Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging
por: Maurer, Alexander, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ftl1c76cftu92uvqoq7kpctbn1